Julia Glade Bender, MD
Vice Chair for Clinical Research
Pediatric Sarcomas; Neuroblastoma; Rare Tumors; Tumors Resistant to Prior Therapy; Early Phase Clinical Trials; Precision Oncology; Adolescents and Young Adults
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Accepted Insurance Providers
Dr. Glade Bender accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- The Empire Indemnity Plan provides limited coverage for our services.
Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, and HMO plans as well as their Enhanced Care Prime Network, which supports Medicaid Managed Care and Child Health Plus and Medicare plans. Memorial Sloan Kettering is also in-network with the New York State Essential Emblem Health plan, which can be purchased on the insurance exchange. Emblem Health does not include us in any of its Medicare plans or in any of its Select Care network plans. You must bring a referral from your Emblem primary care doctor to your first appointment.
Formerly known as Health Plus Amerigroup, Empire Blue Cross Blue Shield Health Plus is an in-network provider with Memorial Sloan Kettering. You will need a one-time referral from your primary care doctor.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We're here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
New York State Medicaid covers physician and hospital services at Memorial Sloan Kettering. Patients are responsible for co-payments.
We also have contractual relationships involving Medicaid Managed Care plans. MSK is an in-network provider with Medicaid NY Emblem Health (formerly known as HIP) and Medicaid NY Empire Blue Cross Blue Shield HealthPlus (formerly known as Amerigroup). You will need a one-time referral from your primary care doctor.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar's Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford's Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Contact and Location
Find a Convenient Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.
MD, University of Pennsylvania School of Medicine
General Pediatrics – Mount Sinai Medical Center
Pediatric Hematology/Oncology – Memorial Sloan Kettering Cancer Center
Pediatric Hematology-Oncology; Pediatrics
I am a pediatric oncologist who specializes in caring for young people with solid tumors of the bone and soft tissues, including osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, germ cell tumors, and other rare tumors. As cliché as it might sound, I love talking to kids of all ages through young adulthood. With five kids of my own, I’ve had a lot of practice. It is both an honor and a privilege to guide patients and their families through what is likely to be the most difficult experience of their lives. There is no greater satisfaction than delivering a child back to the life they were meant to lead and allowing them to become the person they were destined to be.
I am also attracted to the emotional and intellectual challenges of diagnosing, understanding, and treating complex illnesses. To provide the best treatment available and to build the most effective team around a child, I strive to understand each person as an individual. How families communicate, how people cope, and what they need also come into play. With 80 percent of pediatric cancer patients surviving, the context of cancer care during developmental stages can have a profound impact. Kids still need to play like kids. Adolescents and young adults will struggle with issues of independence.
Likewise, there’s a lot about tumor biology that can be translated into better therapies for children. We need to understand what makes an individual tumor tick and shut it down. For many people, standard chemotherapy using existing anticancer drugs will continue to be the best approach. But for others, there’s great hope that newer technologies will result in better biologic and targeted therapies. These advances can take advantage of the differences between tumor cells and normal cells. At Memorial Sloan Kettering, every child’s tumor undergoes genetic sequencing. This testing allows us to quickly identify whether there are newer drugs that can be added to or can replace standard therapies.
My research occurs by the bedside and in the clinic, in the form of clinical trials. I feel strongly that children should have access to drugs in the earliest stages of testing, especially if the drug has been developed to target specific cancer drivers identified in their tumors. At MSK, we have broad expertise and the newest therapies available, including those that help or train the body’s immune system to recognize cancer. We try our best to learn from every patient and share that knowledge. Each patient is an individual. What is good for one may not be the best choice for another.
My overarching goal is to apply research and clinical experience to improve the care of all young people with cancer. I hope that in the future, we can use more-effective therapies with fewer side effects. With my incredible colleagues, I put my heart and mind to work each day for the kids for we are honored to care for. I aim to cure cancer one patient at a time, and I’m not going to stop until we get there.
Awards and Honors
- Castle Connolly: New York Magazine Top Doctors (2014, 2016-2018)
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Clinical Trials Investigated by Dr. Glade Bender
- A Phase I/II Study of LOXO-292 in Pediatric Patients with Recurrent or Persistent RET-Driven Solid Tumors, including Tumors of the Thyroid and Brain
Clinical Trials Co-Investigated by Dr. Glade Bender
- A Phase I/II Study of Humanized 3F8 Bispecific Antibody in Pediatric and Adult Patients with Recurrent or Persistent Neuroblastoma, Osteosarcoma, and Other Solid Tumors
- A Phase II Study of Axitinib and Nivolumab Immunotherapy Together and Individually in Patients with TFE Kidney Cancer
- A Phase II/III Study of Pediatric Liver Cancer Treatments
Find a Clinical Trial for You
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Moreno L, Casanova M, Chisholm JC, Berlanga P, Chastagner PB, Baruchel S, Amoroso L, Gallego Melcón S, Gerber NU, Bisogno G, Fagioli F, Geoerger B, Glade Bender JL, Aerts I, Bergeron C, Hingorani P, Elias I, Simcock M, Ferrara S, Le Bruchec Y, Slepetis R, Chen N, Vassal G. Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer. Eur J Cancer. 2018 Sep;100:27-34. doi: 10.1016/j.ejca.2018.05.002. Epub 2018 Jun 21.
Oberg JA, Ruiz J, Ali‐Shaw T, Schlechtweg KA, Ricci A, Kung AL, Chung WK, Appelbaum PS, Glade Bender JL, Levine JM. Whole‐Genome and Whole‐Exome Sequencing in Pediatric Oncology: An Assessment of Parent and Young Adult Patient Knowledge, Attitudes, and Expectations, JCO Precision Oncology. 2018 :2, 1-11.
Oberg JA*, Glade Bender JL*, Sulis ML*, Pendrick D, Sireci AN, Hsiao SJ, Turk AT, Dela Cruz FS, Hibshoosh H, Remotti H, Zylber RJ, Pang J, Diolaiti D, Koval C, Andrews SJ, Garvin JH, Yamashiro DJ, Chung WK, Emerson SG, Nagy PL, Mansukhani MM, Kung AL. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. Genome Medicine. Genome Medicine. Dec 23, 2016; 8(1):133. DOI: 10.1186/s13073-016-0389-6. [PMID: 28007021] *Contributed equally
Harris MH, DuBois SG, Glade Bender JL, Kim A, Crompton BD, Parker E, Dumont IP, Hong AL, Guo D, Church A, Stegmaier K, Roberts CW, Shusterman S, London WB, MacConaill LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2016 Jan 28. doi: 10.1001/jamaoncol.2015.5689. [Epub ahead of print].
Tannenbaum-Dvir S, Glade-Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS. Characterization of a novel fusion gene 1 EML4-NTRK3 in an aggressive case of congenital fibrosarcoma. Cold Spring Harbor Molecular Case Studies. 2015: a000471.
Voss SD, Glade-Bender J, Spunt SL, DuBois SG, Widemann BC, Park JR, Leary SE, Nelson MD, Adamson PC, Blaney SM, Weigel B. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: A report from the children’s oncology group phase I consortium. Pediatr Blood Cancer. Pediatr Blood Cancer. 2015 Jan;62(1):45-51. [Epub 2014 Sep 24; PMID:25257751].
Glade Bender J, Lee A, Reid JM, Baruchel S, Roberts T, Voss S, Wu B, Ahern C, Ingle AM, Harris P, Weigel B, Blaney SM. A Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children with Refractory Solid Tumors including Soft Tissue Sarcoma: A Children’s Oncology Group Phase I Consortium Report. J Clin Oncol. 2013 Aug 20;31(24):3034-3043. [Epub 2013 Jul 15; PMID: 23857966].
Glade Bender J, Blaney SM, Borinstein SC, Reid JM, Baruchel S, Ahern C, Ingle AM, Yamashiro DJ, Chen A, Weigel B, Adamson PC, Park JR. A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children’s Oncology Group Phase I Consortium Report. Clin Cancer Res. 2012 Sep 15;18(18):5081-9. [PMID: 22791883].
Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Cooney-Qualter EM, Stempak D, Chen HX, Nelson MD, Krailo MD, Ingle AM, Blaney SM, Kandel JJ, Yamashiro DJ. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol. 2008 Jan 20; 26(3):399-405[PMID: 18202416].
Publications on PubMed
Visit PubMed for a full listing of Dr. Glade Bender’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.